Failure of mycophenolate mofetil therapy in primary refractory nephrotic syndrome.
Mycophenolate mofetil (MMF) has been suggested as a promising therapeutic agent in the treatment of idiopathic nephrotic syndrome. Two patients with persistent nephrotic syndrome, secondary to minimal change disease and idiopathic membranous nephropathy, respectively, who were steroid-, cyclophosphamide- and cyclosporine-resistant, were treated with MMF during a 6-12-month period. In these cases there was no beneficial effect from treatment with MMF. Therapy was stopped after 6 months in case 1 and after 12 months in case 2 due to the persistence of proteinuria.
Baglio
Veronica
V
Division of Nephrology, Department of Clinical Sciences, Policlinico Umberto I, Rome, Italy.
Pecci
Gabriella
G
Gangemi
Concetta
C
Barresi
Giusi
G
Morabito
Santo
S
Pierucci
Alessandro
A
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D004351:Drug Resistance; D006801:Humans; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011507:Proteinuria / Q000188:drug therapy; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009173:Mycophenolic Acid